EXCLUSIVE: AzurRx President & CEO Comments On Phase 2 MS1819 Trial, Tells Benzinga ''We anticipate that this new formulation could be used to treat patients with severe EPI, either as a stand-alone monotherapy or as a combination therapy with PERT'